Can you take Beqvez with Rilpivirine?

The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Alcoholic Cirrhosis.

Fidanacogene elaparvovec, a liver-targeting gene therapy, may carry the theoretical risk of hepatocellular carcinoma development. Patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) should be monitored with regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing for 5 years following treatment.

The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Alcoholic Liver Damage.

Fidanacogene elaparvovec, a liver-targeting gene therapy, may carry the theoretical risk of hepatocellular carcinoma development. Patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) should be monitored with regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing for 5 years following treatment.

The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Alcoholism.

Fidanacogene elaparvovec, a liver-targeting gene therapy, may carry the theoretical risk of hepatocellular carcinoma development. Patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) should be monitored with regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing for 5 years following treatment.

Rilpivirine has a moderate potential interaction with Depression.

Depressive symptoms including suicide ideation and suicide attempts have been reported with the use of rilpivirine. Patients should be monitored for the appearance of these symptoms and should seek medical evaluation immediately if severe depressive symptoms occur. Caution should be used in patients with a history of depression or other psychiatric conditions.

The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with HIV-1 Infection.

There is limited information on the safety and effectiveness of fidanacogene elaparvovec in patients with HIV infection. Perform HIV testing prior to infusion, and do not administer this product to patients with either CD4+ cell count less than 200 mm3 or viral load equal to or greater than 20 copies/mL in case of serological evidence of HIV-1 or HIV-2 infection.

The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Infectious Hepatitis.

Fidanacogene elaparvovec, a liver-targeting gene therapy, may carry the theoretical risk of hepatocellular carcinoma development. Patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) should be monitored with regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing for 5 years following treatment.

The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Liver Disease.

Fidanacogene elaparvovec has not been studied in patients with liver dysfunction. Furthermore, administration of this product can lead to liver transaminase elevations and hepatocyte injury. Patients should undergo a liver health assessment prior to treatment, which includes liver function tests, screening for active hepatitis B or C, and elastography and/or ultrasound to assess liver fibrosis. This product should not be administered to patients with current liver-related coagulopathy, hypoalbuminemia, persistent jaundice, or cirrhosis, portal hypertension, splenomegaly, hepatic encephalopathy, hepatic fibrosis, or active viral hepatitis.

Rilpivirine has a moderate potential interaction with Liver Disease.

Hepatic adverse events have been reported in patients taking rilpivirine. Patients with underlying hepatitis B or C virus infection or marked transaminase elevations prior to therapy may be at increased risk for worsening or development of transaminase elevations; a few cases of hepatic toxicity have been reported in patients without preexisting hepatic disease or other known risk factors. Appropriate laboratory testing before starting therapy and monitoring for hepatotoxicity during therapy are recommended in patients with underlying hepatic disease (e.g., hepatitis B or C virus infection) or in patients with marked baseline transaminase elevations. Rilpivirine has not been studied in patients with severe liver dysfunction (Child-Pugh C); caution is recommended.

Rilpivirine has a moderate potential interaction with Psychosis.

Depressive symptoms including suicide ideation and suicide attempts have been reported with the use of rilpivirine. Patients should be monitored for the appearance of these symptoms and should seek medical evaluation immediately if severe depressive symptoms occur. Caution should be used in patients with a history of depression or other psychiatric conditions.

The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Renal Dysfunction.

Fidanacogene elaparvovec has not been studied in patients with renal dysfunction.

Rilpivirine has a moderate potential interaction with Renal Dysfunction.

Rilpivirine should be used with caution and with increased monitoring for side effects in patients with severe renal dysfunction or end-stage renal disease, as drug concentrations can be increased due to alteration of drug absorption, distribution, and metabolism secondary to renal dysfunction. No dose adjustment is required in patients with mild or moderate renal dysfunction.